Financial Statements

Ligand Pharmaceuticals Incorporated (LGND)

$73.61

+0.47 (+0.64%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) 392400-229-401-
Net Income 58-362914313
Stock Dividends -449-5-28-413
Dividend Paid -----
Retained Earnings 0392400-229-401

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 211854-
Annual Depreciation 48151311
Capital Expenditure -9-4-3-12-7
Net PPE 17211854

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -868795190
New Purchases -254-1,434-2,357-423-181
Intangible and Goodwill 868795190735

Ligand Pharmaceuticals Incorporated income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Ligand Pharmaceuticals Incorporated FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.